Pemphigus Foliaceus—Repeated Treatment With Rituximab 7 Years After Initial Response: A Case Report
Pemphigus foliaceus is an autoimmune skin disease mediated by autoantibodies directed against desmoglein-1 located in the upper epidermal layer. Rituximab, a monoclonal anit-CD20 antibody depleting b-cells, offers an effective treatment possibility for therapy-resistant pemphigus foliaceus. Here, we...
Main Authors: | Magdalena Kraft, Margitta Worm |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-11-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fmed.2018.00315/full |
Similar Items
-
Pemphigus foliaceus complicated by Kaposi varicelliform eruption and bilateral herpes simplex keratitis
by: Yu-Jen Huang, et al.
Published: (2018-03-01) -
Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy
by: Gabrielle Benesh, BS, et al.
Published: (2021-10-01) -
Pemphigus foliaceus in a sheep
by: Aline Antas Cordeiro Cavalcanti, et al.
Published: (2019-04-01) -
Pemphigus foliaceus masquerading as IgA pemphigus and responding to dapsone
by: Manas Chatterjee, et al.
Published: (2012-01-01) -
Simultaneous endemic pemphigus foliaceus and psoriasis
vulgaris in Peru – immunogenetic or environmental factors?
by: Willy Ramos, et al.
Published: (2021-06-01)